Types
anti-angiogenic fragments from larger proteins with unrelated functions
- from matrix components such as collagen and fibronectin
- from circulating proteins
- from intracellular proteins
Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis.
Experiences with angiogenesis inhibitors in clinical trials indicate that short-term toxicities are mostly manageable.
However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities.
References
Brandwijk RJ, Griffioen AW, Thijssen VL. Targeted gene-delivery strategies for angiostatic cancer treatment. Trends Mol Med. 2007 May;13(5):200-9. PMID: 17379575
Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007 Jun;7(6):475-85. PMID: 17522716
Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005 May 15;65(10):3967-79. PMID: 15899784
D’Amore PA, Ng YS. Tales of the cryptic: unveiling more angiogenesis inhibitors. Trends Mol Med. 2002 Jul;8(7):313-5. PMID: 12114105